Epidermal growth factor receptor (EGFR) mutations are important drivers of non-small cell lung cancer (NSCLC) tumors. The frequency of EGFR mutations in NSCLC is higher in Asian populations (up to 50–60%) than in Caucasian patients (approximately 10%). Treatment with the first-generation EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib demonstrated longer progression-free survival (PFS), versus platinum-based chemotherapy for first-line treatment of EGFR mutation-positive NSCLC in several randomized trials; however, an overall survival (OS) benefit was not observed.

Afatinib is an oral, irreversible ErbB family blocker of EGFR (ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), ErbB3, and ErbB4 signaling. In contrast to first-generation EGFR TKIs, erlotinib and gefitinib, which are reversible inhibitors of EGFR, afatinib covalently binds to the EGFR, HER2 and ErbB4 receptors, and irreversibly blocks signaling from all ErbB family dimers. Afatinib is approved in Europe for the treatment of EGFR TKI-naive NSCLC patients with EGFR-activating mutations, and in the United States for first-line treatment of NSCLC patients harboring common (Del19 or L858R) mutations, based on the results of two large phase III studies: LUX-Lung 3 and LUX-Lung 6. Each of these studies, which were designed to meet regulatory requirements of different regions, compared afatinib with standard platinum-doublet chemotherapy in patients with metastatic lung adenocarcinoma with activating EGFR mutations. LUX-Lung 3 was a global trial which compared afatinib with cisplatin/pemetrexed in EGFR mutation-positive lung adenocarcinoma patients and overall survival (OS) in Del19 patients. Preplanned analyses in Japanese patients from LUX-Lung 3 were performed. Patients were randomized 2:1 to afatinib or cisplatin/pemetrexed, stratified by mutation type (Del19/L858R/Other). Primary endpoint was PFS (independent review). Secondary endpoints included OS, objective response, and safety. Median PFS (data cut-off: February 2012) for afatinib versus cisplatin/pemetrexed was 13.8 vs 6.9 months (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.20–0.70; P = 0.0014) in all Japanese patients (N = 83), with more pronounced improvements in those with common mutations (Del19/L858R; HR, 0.28; 95% CI, 0.15–0.52; P < 0.0001) and Del19 mutations (HR, 0.16; 95% CI, 0.06–0.39; P < 0.0001). PFS was also improved in L858R patients (HR, 0.50; 95% CI, 0.20–1.25; P = 0.1309). Median OS (data cut-off: November 2013) with afatinib versus cisplatin/pemetrexed was 46.9 vs 35.8 months (HR, 0.75; 95% CI, 0.40–1.43; P = 0.3791) in all Japanese patients, with greater benefit in patients with common mutations (HR, 0.57; 95% CI, 0.29–1.12; P = 0.0966) and Del19 mutations (HR, 0.34; 95% CI, 0.13–0.87; P = 0.0181); OS was not significantly different in L858R patients (HR, 1.13; 95% CI, 0.40–3.21; P = 0.8212). Following study treatment discontinuation, most patients (93.5%) received subsequent anticancer therapy. The most common treatment-related adverse events were diarrhea, rash/acne, nail effects and stomatitis with afatinib and nausea, decreased appetite, neutropenia, and leukopenia with cisplatin/pemetrexed. Afatinib significantly improved PFS versus cisplatin/pemetrexed in Japanese EGFR mutation-positive lung adenocarcinoma patients and OS in Del19 but not L858R patients (www.clinicaltrials.gov; NCT00949650).
longed with afatinib (11.1 months) versus cisplatin/pemetrexed (6.9 months; hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.43–0.78; \(P < 0.001\)). Among 308 patients with common mutations (Del19/L858R), median PFS was 13.6 months with afatinib versus 6.9 months with cisplatin/pemetrexed (HR, 0.47; 95% CI, 0.34–0.65; \(P < 0.001\)). Subgroup analyses of PFS showed a consistent treatment effect for Asian and non-Asian patients. Afatinib was also associated with better control of cough and dyspnea than chemotherapy. The most common treatment-related adverse events (AEs) were diarrhea, rash/acne, and stomatitis with afatinib and nausea, fatigue, and decreased appetite with chemotherapy. In updated OS results from LUX-Lung 3, there was a trend towards an improvement in OS with afatinib in patients with common mutations (31.6 months with afatinib versus 28.2 months with chemotherapy; HR, 0.78; 95% CI, 0.58–1.06; \(P = 0.1090\)) and a significant improvement in OS with afatinib was observed in patients with Del19 mutations (33.3 vs 21.1 months; HR, 0.54; 95% CI, 0.36–0.79; \(P = 0.0015\)). OS results in LUX-Lung 6 were consistent with those in LUX-Lung 3.

We performed a preplanned subgroup analysis of Japanese patients in the LUX-Lung 3 trial to confirm if the efficacy and safety of afatinib in Japanese patients were consistent with the overall patient population.

Materials and Methods

Study design and patients. Details of the study design and methodology of the LUX-Lung 3 trial have been published previously. In brief, LUX-Lung 3 was a phase III, randomized trial in which treatment-naïve patients with stage IIB/IV lung adenocarcinoma and confirmed EGFR mutations were randomized 2:1 to receive afatinib 40 mg daily, or up to six cycles of intravenous cisplatin/pemetrexed at standard doses. Treatment continued until disease progression or unacceptable tolerability. Randomization was stratified by EGFR mutation (Del19 versus L858R versus Other) and race (Asian versus non-Asian). All patients provided informed consent. The study was conducted in accordance with the Declaration of Helsinki and guidelines on Good Clinical Practice and was approved by the institutional review boards of the participating centers.

Endpoints and assessments. The primary endpoint was PFS (independent review). PFS was analyzed after at least 217 progression events. Key secondary endpoints were objective response rate (complete response [CR] or partial response [PR]), disease control rate (CR, PR, or stable disease), and OS. Patient-reported outcomes and safety were also assessed.

Tumor assessments were performed by computed tomography or magnetic resonance imaging every 6 weeks for the first 48 weeks and every 12 weeks thereafter until progressive disease or starting new anticancer therapy. Tumor response was defined using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. AEs were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Treatment compliance with afatinib was assessed from the start to the end of study treatment, after each treatment course, for all patients. Compliance was assessed by counting returned, unused tablets (for recovery from a drug-related AE, interruption of the treatment was allowed and the patient was still regarded as compliant).

Statistical analysis. For the overall LUX-Lung 3 population, sample size was specified assuming an HR of 0.64, equating to an increase in median PFS from an expected 7 months for chemotherapy to 11 months for afatinib. To provide 90% power at a two-sided 5% significance level, a minimum of 217 progression events (by independent review) or deaths was required. Primary and key secondary endpoints were analyzed following a hierarchical testing strategy to minimize the overall risk of type I error. OS analyses were planned for two time points: the first was concurrent with the primary PFS analysis; a Haybittle-Peto stopping boundary was used (\(P < 0.0001\)) to preserve the overall 5% type I error. The second (main) analysis was planned after 209 deaths, when it was estimated that the data would be mature.

All efficacy analyses, including preplanned analyses of the Japanese patients, were performed in an intent-to-treat manner and included all randomized patients. Cox proportional hazards models and stratified log-rank tests were used to compare PFS and OS between treatments, and Kaplan–Meier estimates were calculated. Objective response and disease control rates were compared between treatments via logistic regression models. Preplanned subgroups and analyses were defined, but no adjustment for multiplicity was performed. Median follow-up times were calculated using the reverse Kaplan–Meier method.

Safety analyses included all patients who received at least one dose of trial medication and were performed both at primary PFS analysis and the main OS analysis; the safety results presented here are from the latter time point.

Results

Patient demographics. The study was performed at 133 centers, including 16 centers in Japan. In total, 185 Japanese patients were screened for EGFR mutations. Of these, 83 patients were randomized (54 to afatinib and 29 to cisplatin/pemetrexed) and 82 received treatment (one patient randomized to cisplatin/pemetrexed did not receive treatment; Fig. S1).

Japanese patient demographics were similar across treatment arms (Table 1). Most patients had tumors with common EGFR mutations (47.0% had Del19 mutation and 45.8% had L858R mutation).

Treatment. At the time of the main OS analysis, median treatment duration for Japanese patients receiving afatinib was 419.5 days (range, 28–1323) and six patients are continuing on treatment. Mean overall compliance with afatinib was 96%. Forty-one patients (75.9%) had dose reductions due to AEs; 18 (33.3%) had one dose reduction and 23 (42.6%) had two dose reductions. Median time to first dose reduction was 57.0 days (range, 16–443). Further details on reasons for dose reduction are provided in the Safety section.

Median treatment duration for Japanese patients receiving chemotherapy was 74.0 days. Two patients (7.1%) had one treatment cycle, three (10.7%) had two cycles, three (10.7%) had three cycles, 11 (39.3%) had four cycles, one (3.6%) had five cycles, and eight (28.6%) had six cycles. Of patients receiving ≥1 course of chemotherapy, 10 patients (38.5%) had no treatment delays, two (7.7%) had a worst delay of 4–6 days, and 14 (53.8%) had a worst delay of ≥6 days.

Efficacy. Progression-free survival. At the time of data cutoff for the primary PFS analysis (February 2012), median follow-up time was 16.4 months for Japanese patients; 32 (59.3%) patients in the afatinib group and 20 (69.0%) in the cisplatin/pemetrexed group had progressed or died. Independently-assessed PFS was significantly longer with afatinib than cisplatin/pemetrexed (13.8 vs 6.9 months; HR, 0.38; 95% CI, 0.20–0.70; \(P = 0.0014\); Table 2; Fig. 1a). The improvement in
PFS observed with afatinib versus cisplatin/pemetrexed was more pronounced in Japanese patients with common mutations (13.8 vs 6.9 months; HR, 0.28; 95% CI, 0.15–0.52; P < 0.0001) and those with Del19 mutations (16.4 vs 3.1 months; HR, 0.16; 95% CI, 0.06–0.39; P < 0.0001; Table 2; Fig. 1b,c). Though not statistically significant in this small subgroup, PFS was also improved with afatinib in Japanese patients with L858R mutations (13.7 vs 8.3 months; HR, 0.50; 95% CI, 0.20–1.25; P = 0.1309; Table 2; Fig. 1d).

Progression-free survival results in Japanese patients were consistent across subgroups examined (including gender, age, baseline Eastern Cooperative Oncology Group performance status, and smoking history; Fig S2a).

A post-hoc analysis evaluating PFS in Japanese patients with common EGFR mutations, with or without brain metastases at baseline, was conducted. For patients with common mutations and without brain metastases (n = 61), median PFS was significantly improved with afatinib (16.4 months) versus cisplatin/pemetrexed (8.2 months; HR, 0.26; 95% CI, 0.13–0.55; P = 0.0001). A significant improvement in PFS with afatinib (19.2 months) versus cisplatin/pemetrexed (6.9 months) was observed in patients without brain metastases and with Del19 mutations (n = 32; HR, 0.14; 95% CI, 0.05–0.40; P < 0.0001). Although not statistically significant, PFS was also improved with afatinib (13.8 months) versus cisplatin/pemetrexed (8.3 months) in patients without brain metastases and with L858R mutations (n = 29; HR, 0.56; 95% CI, 0.18–1.80; P = 0.3243). In Japanese patients with brain metastases, median PFS with afatinib versus cisplatin/pemetrexed was 9.0 vs 3.9 months in those with common mutations (n = 15; HR, 0.45; 95% CI, 0.12–1.71; P = 0.2233), 9.5 vs 3.1 months in those with Del19 mutations (n = 7; HR, 0.38; 95% CI, 0.04–4.00; P = 0.4072), and 8.3 vs 7.4 months in patients with L858R mutations (n = 8; HR, 0.51; 95% CI, 0.09–3.11; P = 0.4477).

Objective response and disease control rate. In the overall Japanese population, a significantly higher proportion of patients achieved an objective response with afatinib versus cisplatin/pemetrexed (61.1% vs 20.7%, respectively; odds ratio, 6.52; 95% CI, 2.22–19.14; P = 0.0007; Table 2). Similar results were observed in Japanese patients with common EGFR mutations and those with Del19 or L858R mutations (Table 2).

Disease control rates were high for both treatment arms (96.3% for afatinib and 89.7% for cisplatin/pemetrexed). Results were consistent when evaluated according to EGFR mutation status (Table 2).

Overall survival. At the time of data cut-off for the main OS analysis (November 2013), median follow-up time was 41.0 months for Japanese patients. Twenty-four (44.4%) afatinib-treated patients and 16 (55.2%) cisplatin/pemetrexed-treated patients had died. There was a trend towards an improvement in median OS with afatinib versus cisplatin/pemetrexed, although this was not statistically significant (46.9 vs 35.8 months, respectively; HR, 0.75; 95% CI, 0.40–1.43; P = 0.3791; Table 2, Fig. 2a). Compared with the overall Japanese population, a more pronounced OS benefit for afatinib versus cisplatin/pemetrexed was observed in patients with common mutations (46.9 vs 35.0 months, respectively; HR, 0.57; 95% CI, 0.29–1.12; P = 0.0966; Table 2, Fig. 2b). In Japanese patients with Del19 mutation, median OS was significantly improved with afatinib (46.9 vs 31.5 months; HR 0.34; 95% CI, 0.13–0.87; P = 0.0181; Table 2, Fig. 2c), while in patients with L858R mutation, OS was similar between treatment arms (41.7 months with afatinib and 40.3 months with cisplatin/pemetrexed; HR, 1.13; 95% CI, 0.40–3.21; P = 0.8212; Table 2, Fig. 2d).

Overall survival results in Japanese patients were consistent across subgroups (Fig S2b). In addition to the greater benefit observed in patients with Del19 mutations, female patients appeared to derive greater OS benefit from afatinib; however, this effect may be confounded with the mutation type effect, as a greater proportion of afatinib-treated female patients had a Del19 mutation compared with males.

Following discontinuation of the study drug, all Japanese patients receiving chemotherapy received a subsequent anticancer therapy. Of patients in the overall Japanese population who discontinued afatinib, 43/48 patients (89.6%) received a new anticancer therapy, with 77.1% receiving chemotherapy (Table S1).

Safety. An overall summary of AEs is shown in Table S2. The most common treatment-related AEs were diarrhea, rash/acne, nail effects, and stomatitis with afatinib and nausea, decreased appetite, neutropenia, and leukopenia with cisplatin/pemetrexed. Drug-related AEs of ≥grade 3 occurred in 37 patients (68.5%) in the afatinib group and 19 (35.0%) in the cisplatin/pemetrexed group (Table 3).

Adverse events leading to dose reduction occurred in 41 (75.9%) afatinib-treated Japanese patients and five (17.9%) chemotherapy-treated patients (Table S2). The most common AEs leading to afatinib dose reduction were nail effects (n = 17; 31.5%), rash/acne (n = 15; 27.8%), and diarrhea (n = 12; 22.2%). Ten patients (18.5%) receiving afatinib and seven patients (25.0%) receiving chemotherapy had an AE leading to discontinuation of study treatment. No treatment-related discontinuations with afatinib were due to an AE of diarrhea or rash/acne (Table S3).
Table 2. Efficacy of afatinib versus cisplatin + pemetrexed in the overall Japanese population and in subgroups based on EGFR mutation category (common mutations, L858R mutations and Del19 mutations)

|                        | Overall Japanese population | Japanese patients with common mutations | Japanese patients with Del19 mutation | Japanese patients with L858R mutation | Overall LUX-Lung 3 population<sup>(23,26)</sup> |
|------------------------|-----------------------------|-----------------------------------------|--------------------------------------|--------------------------------------|-------------------------------------------|
|                        | Afatinib        | CT          | Afatinib        | CT          | Afatinib        | CT          | Afatinib        | CT          | Afatinib        | CT          |
| Patients, n (%)        | 54              | 29          | 50              | 27          | 23              | 16          | 27              | 11          | 230             | 115         |
| Data cut-off: February 2012 |                |             |                  |             |                  |             |                  |              |                  |             |
| Median PFS, months (95% CI) | 13.8 (11.0–19.1)   | 6.9 (3.1–8.8)  | 13.8 (12.7–19.1) | 6.9 (2.8–8.3) | 16.4 (11.0–NE) | 3.1 (2.6–8.2) | 13.7 (8.1–19.1) | 8.3 (2.4–13.7) | 11.1 (9.6–13.6) | 6.9 (5.4–8.3) |
| HR (95% CI); P-value   | 0.38 (0.20–0.70); 0.0014 | 0.28 (0.15–0.52); <0.0001 | 0.16 (0.06–0.39); <0.0001 | 0.50 (0.20–1.25); 0.1309 | 0.58 (0.43–0.78); 0.0004 |
| Objective response, n (%) | 33 (61.1) | 6 (20.7) | 32 (64.0) | 6 (22.2) | 16 (69.6) | 4 (25.0) | 16 (59.3) | 2 (18.2) | 129 (56.1) | 26 (22.6) |
| OR (95% CI); P-value   | 6.52 (2.22–19.14); 0.0007 | 6.22 (2.12–18.24); 0.0009 | 6.86 (1.63–28.90); 0.0087 | 6.55 (1.18–36.32); 0.0317 | 4.66 (2.77–7.83); <0.0001 |
| Disease control, n (%)  | 52 (96.3) | 26 (89.7) | 50 (100.0) | 24 (88.9) | 23 (100.0) | 14 (87.5) | 27 (100.0) | 10 (90.9) | 207 (90.0) | 93 (80.9) |
| OR (95% CI); P-value   | 3.10 (0.46–20.93); 0.2462 | NE          | NE          | NE          | 2.14 (1.13–4.04); 0.0189 |
| Data cut-off: November 2013 |                |             |                  |             |                  |             |                  |              |                  |             |
| Median OS, months (95% CI) | 46.9 (35.1–NE) | 35.8 (28.6–NE) | 46.9 (35.3–NE) | 35.0 (28.2–NE) | 46.9 (35.1–46.9) | 31.5 (14.0–NE) | 41.7 (24.2–NE) | 40.3 (28.2–NE) | 28.2 (24.6–33.6) | 28.2 (20.7–33.2) |
| HR (95% CI); P-value   | 0.75 (0.40–1.43); 0.3791 | 0.57 (0.29–1.12); 0.0966 | 0.34 (0.13–0.87); 0.0181 | 1.13 (0.40–3.21); 0.8212 | 0.88 (0.66–1.17); 0.3850 |

CI, confidence interval; CT, chemotherapy; HR, hazard ratio; NE, not estimable; OR, odds ratio; OS, overall survival; PFS, progression-free survival.
The incidence of diarrhea and rash was significantly higher in Japanese patients receiving afatinib versus those receiving cisplatin/pemetrexed (Table S3). Time to first onset of diarrhea or rash/acne was 1–14 days after starting afatinib for most patients (Table S3). AEs of diarrhea and rash/acne were managed through standard therapy and dose reductions. Dose reductions enabled patients to remain on afatinib for as long as they experienced clinical benefit (Fig. 3).

Two Japanese patients receiving afatinib experienced drug-related interstitial lung disease (ILD) or an ILD-like event, and afatinib was discontinued. A patient with grade 3 interstitial pneumonia recovered after a course of antibiotics and corticosteroids, while another case (grade 1 ILD) resolved without supportive treatment.

There were no on-treatment deaths in either group. Ten (18.5%) afatinib-treated patients and four (14.3%) cisplatin/pemetrexed-treated patients experienced serious AEs (six [11.1%] and three [10.7%], respectively, were considered treatment-related).

Discussion

Afatinib significantly improved PFS and objective response versus cisplatin/pemetrexed in Japanese patients with EGFR mutation-positive NSCLC. The benefits of afatinib on PFS and objective response were observed for patients harboring either type of common EGFR mutation (Del19 or L858R). Based on these data, afatinib was approved for the treatment of EGFR mutation-positive inoperable or recurrent NSCLC in Japan. There was a trend towards an improvement in OS with afatinib versus cisplatin/pemetrexed in the overall Japanese population and those with common mutations. OS was significantly improved in Japanese patients with Del19 mutation, while in patients with L858R mutation OS was similar between treatment arms.

LUX-Lung 3 is one of the largest prospective randomized trials conducted in patients with advanced EGFR mutation-positive NSCLC and the Japanese subgroup was one of the largest country groups included. Analysis is limited by the fact...
that this is a subgroup analysis with smaller patient numbers and, therefore, less power to identify potential differences between treatment groups.

Nevertheless, the clinical benefits of afatinib over chemotherapy observed in Japanese patients were consistent with the results observed in the global population of the LUX-Lung 3 trial. However, numerically longer median OS in both treatment arms was observed in Japanese patients versus the LUX-Lung 3 population as a whole (Table 2). There could be a number of reasons for this improved efficacy, one being that Japan has an effective and easily accessible health system versus countries which do not have universal reimbursement policies. This is reflected in the subsequent therapies that Japanese patients received; for example, all chemotherapy-treated patients with common mutations received an EGFR TKI following disease progression and approximately 90% of afatinib-treated patients received subsequent therapy after discontinuing study treatment, which were covered by health insurances (Table S1). Despite the high rate of subsequent EGFR TKI therapy received by patients in the cisplatin/pemetrexed arm following discontinuation of study treatment, afatinib was still associated with numerically improved OS versus chemotherapy in the overall Japanese population (46.9 vs 35.8 months, respectively) and significantly improved OS in those with Del19 mutations (46.9 vs 31.5 months, respectively).

Improvements in PFS versus chemotherapy in Japanese patients have been observed with erlotinib and gefitinib, although median PFS was numerically longer with afatinib (13.8 months) in the current study. In a phase III trial (NEJ002) conducted in Japan, patients with EGFR mutation-positive metastatic NSCLC were randomized to gefitinib or carboplatin/paclitaxel. In a planned interim analysis of the first 200 patients median PFS was 10.8 months with first-line gefitinib versus 5.4 months with carboplatin/paclitaxel. Similarly, in a phase III trial (WJTOG3405) with 177 chemotherapy-naive Japanese

Fig. 2. OS for afatinib versus cisplatin/pemetrexed. (a) All randomized Japanese patients. (b) Japanese patients with common (Del19/L858R) mutations. (c) Japanese patients with Del19 mutation only. (d) Japanese patients with L858R mutation only. CI, confidence interval; HR, hazard ratio; OS, overall survival.
patients with advanced NSCLC or postoperative recurrence with common (Del19/L858R) mutations, gefitinib was associated with median PFS of 9.2 months. Erlotinib, as first-line treatment of 102 Japanese patients with tumors with common EGFR mutations was associated with median PFS of 11.8 months in a single-arm, phase II trial (JO22903). Despite the PFS benefits reported for reversible EGFR TKIs over chemotherapy, improvements in OS have not been observed. Median survival for all 228 patients in the NEJ002 trial was 27.7 months for gefitinib versus 26.6 months for carboplatin/paclitaxel.

Table 3. Most common treatment-related AEs with afatinib and cisplatin + pemetrexed with incidence of ≥20% (maximum grade of AE shown)

| AE                              | Total (n = 54) | Afatinib | Cisplatin + pemetrexed (n = 28) |
|---------------------------------|---------------|----------|---------------------------------|
|                                 | All grades | Grade 1 | Grade 2 | Grade 3 | Grade 4 | All grades | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
| Total                           | 54 (100.0) | 0 (0)   | 17 (31.5) | 36 (66.7) | 1 (1.9) | 28 (100.0) | 0 (0)   | 9 (32.1) | 15 (53.6) | 4 (14.3) |
| Symptomatic AEs                 |             |         |         |         |         |             |         |         |         |         |
| Diarrhea                        | 54 (100.0) | 21 (38.9) | 21 (38.9) | 12 (22.2) | 0 (0) | 4 (14.3) | 3 (10.7) | 1 (3.6) | 0 (0) | 0 (0) |
| Rash/acne*                      | 54 (100.0) | 12 (22.2) | 31 (57.4) | 11 (20.4) | 0 (0) | 3 (10.7) | 2 (7.1) | 1 (3.6) | 0 (0) | 0 (0) |
| Nail effect*                    | 50 (92.6) | 7 (13.0) | 29 (53.7) | 14 (25.9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Stomatitis*                     | 49 (90.7) | 30 (55.6) | 15 (27.8) | 4 (7.4) | 0 (0) | 7 (25.0) | 7 (25.0) | 0 (0) | 0 (0) | 0 (0) |
| Dry skin                        | 25 (46.3) | 13 (24.1) | 12 (22.2) | 0 (0) | 0 (0) | 1 (3.6) | 1 (3.6) | 0 (0) | 0 (0) | 0 (0) |
| Ocular effect*                  | 23 (42.6) | 13 (24.1) | 9 (16.7) | 1 (1.9) | 0 (0) | 2 (7.1) | 1 (3.6) | 1 (3.6) | 0 (0) | 0 (0) |
| Decreased appetite              | 22 (40.7) | 12 (22.2) | 6 (11.1) | 4 (7.4) | 0 (0) | 22 (78.6) | 13 (46.4) | 8 (28.6) | 1 (3.6) | 0 (0) |
| Lip effect*                     | 20 (37.0) | 10 (18.5) | 10 (18.5) | 0 (0) | 0 (0) | 2 (7.1) | 2 (7.1) | 0 (0) | 0 (0) | 0 (0) |
| Fatigue*                        | 14 (25.9) | 10 (18.5) | 2 (3.7) | 2 (3.7) | 0 (0) | 14 (50.0) | 10 (35.7) | 3 (10.7) | 1 (3.6) | 0 (0) |
| Nausea                          | 13 (24.1) | 8 (14.8) | 4 (7.4) | 1 (1.9) | 0 (0) | 25 (89.3) | 13 (46.4) | 11 (39.3) | 1 (3.6) | 0 (0) |
| Weight decreased                | 13 (24.1) | 4 (7.4) | 9 (16.7) | 0 (0) | 0 (0) | 3 (10.7) | 2 (7.1) | 1 (3.6) | 0 (0) | 0 (0) |
| Epistaxis                       | 12 (22.2) | 11 (20.4) | 1 (1.9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Pruritus                        | 11 (20.4) | 6 (11.1) | 5 (9.3) | 0 (0) | 0 (0) | 1 (3.6) | 1 (3.6) | 0 (0) | 0 (0) | 0 (0) |
| Vomiting                        | 11 (20.4) | 8 (14.8) | 3 (5.6) | 0 (0) | 0 (0) | 12 (42.9) | 8 (28.6) | 3 (10.7) | 1 (3.6) | 0 (0) |
| Alopecia                        | 7 (13.0) | 7 (13.0) | 0 (0) | 0 (0) | 0 (0) | 6 (21.4) | 6 (21.4) | 0 (0) | 0 (0) | 0 (0) |
| Constipation                    | 3 (5.6) | 2 (3.7) | 1 (1.9) | 0 (0) | 0 (0) | 12 (42.9) | 10 (35.7) | 2 (7.1) | 0 (0) | 0 (0) |
| Headache                        | 3 (5.6) | 3 (5.6) | 0 (0) | 0 (0) | 0 (0) | 7 (25.0) | 7 (25.0) | 0 (0) | 0 (0) | 0 (0) |
| Hiccups                         | 1 (1.9) | 1 (1.9) | 0 (0) | 0 (0) | 0 (0) | 7 (25.0) | 5 (17.9) | 2 (7.1) | 0 (0) | 0 (0) |
| Edema                           | 1 (1.9) | 1 (1.9) | 0 (0) | 0 (0) | 0 (0) | 7 (25.0) | 7 (25.0) | 0 (0) | 0 (0) | 0 (0) |
| Laboratory or hematologic AEs   |             |         |         |         |         |             |         |         |         |         |
| Leukopenia                      | 3 (5.6) | 0 (0) | 2 (3.7) | 1 (1.9) | 0 (0) | 16 (57.1) | 2 (7.1) | 7 (25.0) | 7 (25.0) | 0 (0) |
| Hemoglobin decreased            | 2 (3.7) | 1 (1.9) | 1 (1.9) | 0 (0) | 0 (0) | 9 (32.1) | 1 (3.6) | 5 (17.9) | 2 (7.1) | 1 (3.6) |
| Anemia                          | 1 (1.9) | 0 (0) | 1 (1.9) | 0 (0) | 0 (0) | 10 (35.7) | 5 (17.9) | 3 (10.7) | 2 (7.1) | 0 (0) |
| Blood creatinine increased      | 1 (1.9) | 1 (1.9) | 0 (0) | 0 (0) | 0 (0) | 6 (21.4) | 3 (10.7) | 3 (10.7) | 0 (0) | 0 (0) |
| Neutropenia                     | 1 (1.9) | 0 (0) | 0 (0) | 1 (1.9) | 0 (0) | 20 (71.4) | 1 (3.6) | 5 (17.9) | 11 (39.3) | 3 (10.7) |
| Thrombocytopenia                | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 (21.4) | 3 (10.7) | 2 (7.1) | 1 (3.6) | 0 (0) |

*Grouped term. AEs, adverse events.

Fig. 3. Treatment duration and afatinib dosage for Japanese patients in the overall population. Stars represent dose reductions due to diarrhea; circles represent dose reductions due to rash/acne; and triangles represent dose reductions due to rash/acne and diarrhea.
A tendency towards improved efficacy outcomes with reversible EGFR TKIs in patients whose tumors harbor Del19 mutations, versus those with L858R mutations, has been previously observed. Retrospective analysis of five clinical trials with patients receiving first-line erlotinib or gefitinib for NSCLC illustrated that Del19 mutations were associated with improved outcomes versus L858R mutations.\(^{11}\) Although this registry was conducted using mainly Western populations, our results in a Japanese subgroup support this differential benefit between patients with Del19 mutation and L858R mutation. Similarly, in the JO22903 trial of erlotinib in Japanese patients, PFS was longer in patients with Del19 mutations than those with L858R mutations.\(^{30}\) The difference in outcomes between Del19 and L858R requires further research; however, preclinical studies suggest that Del19 and L858R mutations have different biological properties, with patterns of EGFR amplification and EGFR autophosphorylation differing between cell lines containing these mutations.\(^{32,33}\)

Previous studies have not suggested substantial differences in efficacy with chemotherapy between mutation types (median PFS ranged from 4.3–5.6 months with chemotherapy in Del19 patients and 5.8–6.8 months in those with L858R mutations).\(^{8,17,18}\) While comparison of the median values suggests that patients with Del19 mutations in our study had a poorer response to chemotherapy than those with L858R mutations, this may be partly due to the nature of a subgroup analysis. As noted earlier, this is a limitation of our study and results in relatively small patient numbers within the Del19 and L858R groups, wherein individual patient data can have a large impact on the median values. This is exemplified by the wide CIs observed for the median PFS and OS values in the Del19 and L858R subgroups (Table 2). Rather, the HRs and supporting Kaplan–Meier curves provide a more reliable summary of the PFS/OS data across the entire observation period. It should also be noted that differences in OS across the mutation groups for chemotherapy may be affected by multiple post-progression therapies. Overall, results in Japanese patients in this analysis, are generally consistent with those observed in the overall global population of LUX-Lung 3, and the similarly-designed LUX-Lung 6 trial,\(^{23,24,26}\) supporting the conclusion that afatinib significantly improves PFS versus chemotherapy in Japanese patients with EGFR mutation-positive lung cancer, and OS in Del19 patients.

The most common treatment-related AEs (all-grade) with afatinib in the Japanese population were diarrhea (100.0%), rash/acne (100.0%), nail effects (92.6%), and stomatitis (90.7%). This is generally consistent with the safety profile observed in the overall LUX-Lung 3 trial, although the frequency of AEs was lower in the overall population (diarrhea, 95.2%; rash/acne, 89.1%; stomatitis/mucositis 72.1% and nail effects, 61.1%).\(^{23}\) Although grade 3 diarrhea and rash/acne occurred in Japanese patients receiving afatinib, these AEs did not lead to discontinuation. Time to first onset of diarrhea or rash/acne was within 14 days after starting afatinib for most patients; as such, early preventative treatments are essential. Of note, there was a local protocol amendment for diarrhea in Japan, with grade 2 diarrhea allowed to persist for 7 days (rather than 2 days) before dose reduction. Compared with the overall LUX-Lung 3 population, Japanese patients were more likely to have an AE leading to dose reduction (57.2% vs 75.9%, respectively). As such, there was greater use of afatinib 20 mg in Japanese patients than in the overall population. Dose reductions with afatinib enabled patients to remain on treatment while they were experiencing clinical benefit. Among three patients who reported drug-related ILD-like events in LUX-Lung 3,\(^{23}\) two were Japanese.

In conclusion, first-line treatment with afatinib was associated with significant PFS and tumor response improvements versus cisplatin/pemetrexed in Japanese patients with advanced EGFR mutation-positive NSCLC. Although all patients in the cisplatin/pemetrexed arm received subsequent anticancer therapy following discontinuation of study treatment, a trend toward improved OS with afatinib was observed in the overall Japanese population, with significant improvements in median OS (<15 months) seen in those with tumors harboring Del19 mutation (46.9 vs 31.5 months) and similar OS observed in patients with L858R mutation (41.7 vs 40.3 months). Safety of afatinib in Japanese patients was consistent with the overall population; AEs were manageable with standard therapy and dose reductions. Based on these findings, afatinib should be the preferred first-line treatment for Japanese patients with advanced NSCLC harboring the EGFR Del19 mutation and an option for patients with the L858R mutation.

Acknowledgments

Medical writing assistance provided by Caroline Allinson of GeoMed, an Ashfield Company, part of UDG Healthcare plc, was funded by Boehringer Ingelheim.

Disclosure Statement

T.K. has received honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical Co., Pfizer, Taiho Pharmaceutical and Ono. He has also received research funding from Boehringer Ingelheim, Chugai Pharmaceutical Co., AstraZeneca, Takeda, Taiho Pharmaceutical, Kirin-Kyowa, Shionogi, Bristol-Myers Squibb and Eli Lilly. H.Y. has received honoraria from Boehringer Ingelheim and Eli Lilly. I.O. has received honoraria from Chugai Pharmaceutical co., Pfizer and Eli Lilly. A.Y. reports no conflicts of interest. T.H. has received honoraria from Nippon Boehringer Ingelheim and research funding from Chugai Pharmaceutical Co., AstraZeneca and Nippon Boehringer Ingelheim and Pfizer. T.S. has received research funding from Nippon Boehringer Ingelheim. K.K. has received honoraria from Boehringer Ingelheim, Chugai Pharmaceutical Co. and AstraZeneca and research funding from Boehringer Ingelheim and Chugai Pharmaceutical Co. D.M. is an employee of Boehringer Ingelheim. Y.S. is an employee of Nippon Boehringer Ingelheim. N.Y. has received honoraria and research funding from Boehringer Ingelheim. The study was designed under the responsibility of Boehringer Ingelheim, in conjunction with the LUX-Lung 3 steering committee, and was also funded by Boehringer Ingelheim (www.clinicaltrials.gov; NCT00949630). Boehringer Ingelheim collected and analyzed the data, and contributed to the interpretation of the study, with input from all authors. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.

Abbreviations

AE adverse event
CI confidence interval
CR complete response
CT chemotherapy
CTC common terminology criteria
disc discontinuation
ECOG PS | Eastern Cooperative Oncology Group performance status
EGFR | epidermal growth factor receptor
HER2/ErbB2 | human epidermal growth factor receptor 2
ILD | interstitial lung disease
NSCLC | non-small cell lung cancer
OR | odds ratio

References

1. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513–20.
2. Chou TY, Chiu CH, Li LH et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 3750–7.
3. Seo JS, Ju YS, Lee WC et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012; 22: 2109–19.
4. Yang SH, Mechanic LE, Yang P et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005; 11: 2106–10.
5. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57.
6. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–8.
7. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTG03405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8.
8. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EUTRACT): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239–46.
9. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 735–42.
10. Han JY, Park K, Kim SW et al. First-SIGNAL: first-line single-agent irressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30: 1122–8.
11. Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin-paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866–74.
12. Inoue A, Kobayashi K, Maemondo M et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013; 24: 54–9.
13. Mitsudomi T, Morita S, Yatabe Y et al. Updated overall survival results of WJTG03405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol 2012; 30: abstract 7521.
14. Genentech. TARCEVA® (erlotinib) tablets, for oral use [prescribing information]. 2014. Cited (14 Aug 2014.) Available from: URL: http://www.gene.com/publications/pdfs/prescribing/ger292003.pdf
15. Zhou C, Wu YL, Liu X et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30: abstract 7520.
16. Yoshioka H, Mitsudomi T, Morita S et al. Final overall survival results of WJTG03405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol 2014; 32: abstract 8117.
17. Wu Y-L, Lian C-K, Zhou C et al. First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): interim analyses from the phase 3, open-label, ENSURE study. J Thorac Oncol 2013; 8: abstract S603.
18. Yang J, Wu YL, Saigo S et al. Efficacy outcomes in first-line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene-copy number score and by most common EGFR mutation subtypes – exploratory data from IPASS. Eur J Cancer 2011; 47: abstract S633.
19. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR /HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702–11.
20. Solca F, Dahl G, Zoepfel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012; 343: 342–50.
21. European Medicines Agency. Giotript - European public assessment report (product information). [Cited 19 Nov 2014.] Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002280/WC500152392.pdf.
22. Boehringer Ingelheim. Gilotrif® prescribing information. [Cited 4 Feb 2013.] Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/22922d001bl.pdf.
23. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327–34.
24. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213–22.
25. Yang JC, Hirsh V, Schuler M et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3342–50.
26. Yang JC, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141–51.
27. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47.
28. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 3.0. Available from URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
29. Fukawa T. Public health insurance in Japan. [Cited 3 Jun 2014.] Available from URL: http://unpan1.un.org/intradoc/groups/public/documents/apcity/unpan02063.pdf.
30. Goto K, Nishio M, Yamamoto N et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC). Lung Cancer 2013; 82: 109–14.
31. Jackman DM, Miller VA, Cioffredi L et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Lung Cancer 2009; 15: 5267–73.
32. Okabe T, Okamoto I, Tamura K et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 2007; 67: 2046–53.
33. Regnart N, Remon J. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine-kinase inhibitors. Future Oncol 2015; 11: 1245–57.

Supporting Information

Additional supporting information may be found in the online version of this article:

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
Fig. S1. Patient disposition at the time of OS analysis (data cut-off: November 2013). OS, overall survival.

Fig. S2. Forest plot of subgroups of Japanese patients showing (a) PFS by independent review and (b) OS. ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; yrs, years.

Table S1. Summary of subsequent anticancer therapy after discontinuing study treatment (data cut-off: November 2013) *Patients received erlotinib or gefitinib in a combination regimen. EGFR, epidermal growth factor receptor; disc, discontinuation; TKI, tyrosine kinase inhibitor.

Table S2. Overall summary of AEs among Japanese patients receiving afatinib or cisplatin + pemetrexed (data cut-off November 2013) AEs, adverse events; CTC, common terminology criteria.

Table S3. Frequency of diarrhea and rash/acne (data cut-off: November 2013) *Number of patients with initial onset within the interval (cumulative Kaplan–Meier estimate % of AE onset by interval end). AE, adverse event; CI, confidence interval; CTC, common terminology criteria; HR, hazard ratio.